Apexigen, Inc. (APGN) Income Statement Analysis

See more : AstraZeneca PLC (AZN.L) Income Statement Analysis – Financial Results

Complete financial analysis of Apexigen, Inc. (APGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apexigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Apexigen, Inc. (APGN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.apexigen.com

About Apexigen, Inc.

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.

Metric	2022	2021	2020
Revenue	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%
Research & Development	23.04M	21.66M	18.77M
General & Administrative	9.65M	7.29M	5.77M
Selling & Marketing	0.00	0.00	0.00
SG&A	9.65M	7.29M	5.77M
Other Expenses	617.00K	0.00	0.00
Operating Expenses	32.69M	28.96M	24.54M
Cost & Expenses	32.69M	28.96M	24.54M
Interest Income	0.00	41.00K	421.00K
Interest Expense	-617.00K	0.00	0.00
Depreciation & Amortization	110.00K	105.00K	127.00K
EBITDA	-32.58M	-28.85M	-24.42M
EBITDA Ratio	0.00%	0.00%	0.00%
Operating Income	-32.69M	-28.96M	-24.54M
Operating Income Ratio	0.00%	0.00%	0.00%
Total Other Income/Expenses	617.00K	41.00K	421.00K
Income Before Tax	-32.07M	-28.92M	-24.12M
Income Before Tax Ratio	0.00%	0.00%	0.00%
Income Tax Expense	-617.00K	-41.00K	-421.00K
Net Income	-31.45M	-28.88M	-23.70M
Net Income Ratio	0.00%	0.00%	0.00%
EPS	-1.59	-0.93	-0.76
EPS Diluted	-1.59	-0.93	-0.76
Weighted Avg Shares Out	19.79M	31.07M	31.07M
Weighted Avg Shares Out (Dil)	19.79M	31.07M	31.07M

Form 8.3 - APPLEGREEN PLC

January 28, 2021businesswire.com

NEW YORK--(BUSINESS WIRE)-- FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person...

Form 8.3 - APPLEGREEN PLC

January 28, 2021businesswire.com

LONDON--(BUSINESS WIRE)-- Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Barclays PLC. APPLEGREEN...

Form 8.3 - Applegreen PLC

January 27, 2021businesswire.com

LONDON--(BUSINESS WIRE)-- FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Name of person dealing (Note 1) Bardin...

Form 8.3 - Applegreen PLC

January 26, 2021businesswire.com

Form 8.3 - APPLEGREEN PLC

January 26, 2021businesswire.com

FORM 8.3 - APPLEGREEN PLC

January 26, 2021businesswire.com

Form 8.3 - APPLEGREEN PLC

January 25, 2021businesswire.com

Form 8.3 - APPLEGREEN PLC

January 22, 2021businesswire.com

Form 8.3 - APPLEGREEN PLC AMENDMENT

January 22, 2021businesswire.com

LONDON--(BUSINESS WIRE)-- Ap19 FORM 8.3 Amendment to Purchase IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION...